Education
About Us
Working with TipRanks
Follow Us
Immucell (ICCC)
:ICCC
ICCC Stock Chart & Stats
$6.16
-$0.45(-8.32%)
At close: 4:00 PM EST
$6.16
-$0.45(-8.32%)
Day’s Range― - ―
52-Week Range$3.40 - $7.60
Previous CloseN/A
Volume9.49K
Average Volume (3M)19.18K
Market Cap
$48.85M
Enterprise ValueN/A
Total Cash (Recent Filing)$6.00M
Total Debt (Recent Filing)$14.27M
Price to Earnings (P/E)20.9
Beta-0.40
Next Earnings
Feb 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding9,045,851
10 Day Avg. Volume12,532
30 Day Avg. Volume19,183
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.53
Price to Sales (P/S)1.59
P/FCF Ratio-390.09
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Immucell News
ICCC FAQ
What was Immucell’s price range in the past 12 months?
Immucell lowest stock price was $3.40 and its highest was $7.60 in the past 12 months.
What is Immucell’s market cap?
Immucell’s market cap is $48.85M.
When is Immucell’s upcoming earnings report date?
Immucell’s upcoming earnings report date is Feb 24, 2026 which is in 101 days.
How were Immucell’s earnings last quarter?
Immucell released its earnings results on Nov 13, 2025. The company reported -$0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.015.
Is Immucell overvalued?
According to Wall Street analysts Immucell’s price is currently Overvalued.
Does Immucell pay dividends?
Immucell does not currently pay dividends.
What is Immucell’s EPS estimate?
Immucell’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell have?
Immucell has 9,045,851 shares outstanding.
What happened to Immucell’s price movement after its last earnings report?
Immucell reported an EPS of -$0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.744%.
Which hedge fund is a major shareholder of Immucell?
Currently, no hedge funds are holding shares in ICCC
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.00%
12-Months-Change
Fundamentals
Return on Equity
8.27%
Trailing 12-Months
Asset Growth
2.88%
Trailing 12-Months
Company Description
Immucell
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
ICCC Company Deck
ICCC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a positive turnaround in financial performance with improved net income, gross margins, and operational efficiency. Domestic sales show positive momentum, and there is optimism surrounding the new leadership. However, challenges remain with declining total product sales and international sales, as well as inventory management concerns.View all ICCC earnings summariesTechnical Analysis
Medicinova
―
Adicet Bio
―
Werewolf Therapeutics
―
Telomir Pharmaceuticals, Inc.
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
0.05% Insiders
4.51% Mutual Funds
0.12% Other Institutional Investors
92.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---